Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Application of biguanide drugs in preparation of drugs for preventing or weakening pulmonary fibrosis

A biguanide drug, pulmonary fibrosis technology, applied in the direction of drug combination, respiratory system diseases, etc., to achieve good stability, prevent or slow down the occurrence and development, stable drug release effect

Inactive Publication Date: 2016-11-23
THE THIRD AFFILIATED HOSPITAL OF THIRD MILITARY MEDICAL UNIV OF PLA
View PDF6 Cites 5 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0005] At present, no literature has been found to report the application of biguanide drugs, mainly metformin, in the preparation of drugs for preventing or weakening pulmonary fibrosis

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of biguanide drugs in preparation of drugs for preventing or weakening pulmonary fibrosis
  • Application of biguanide drugs in preparation of drugs for preventing or weakening pulmonary fibrosis
  • Application of biguanide drugs in preparation of drugs for preventing or weakening pulmonary fibrosis

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0030] Example 1 A metformin sustained-release tablet

[0031]

[0032] Prepare according to conventional methods.

Embodiment 2

[0033] Example 2 A metformin sustained-release tablet

[0034]

[0035] Prepare according to conventional methods.

[0036] Animal experiment

experiment example 1

[0037] Experimental Example 1 Metformin Significantly Attenuates Pulmonary Fibrosis Induced by Transforming Growth Factor β (TGF-β)

[0038] 1.1 Experimental method

[0039] The lung fibroblast cell line HFL-1 was randomly divided into four groups, namely control group, TGF-β group, metformin group and TGF-β+metformin group;

[0040] The control group had no special treatment; the TGF-β group was given TGF-β treatment (10 μg / L, action time 48 h); the metformin group was given metformin treatment (10 μM, action time 48 h); the TGF-β + metformin group was given TGF-β combined with metformin Treatment (10μg / L+10μM, action time 48h);

[0041] After 48 hours, immunofluorescence technique was used to detect the expression of pulmonary fibrosis index α-actin; Western blot technique was used to detect the expression of pulmonary fibrosis marker α-actin, COL1A1 and TGF-β downstream key signaling pathway proteins.

[0042] 1.2 Experimental results

[0043] From figure 1 It can be se...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention relates to new application of biguanide drugs, in particular to application of biguanide drugs in preparation of drugs for preventing or weakening pulmonary fibrosis. The pulmonary fibrosis is complications produced by EGFR-TKI or ALK-TKI in treatment of non-small cell lung cancers. The biguanide drugs can avoid the complications produced by the EGFR-TKI or ALK-TKI in treatment of non-small cell lung cancers, effectively improve an EGFR-TKI or ALK-TKI treatment effect and reduce occurrence and development of patients' complications.

Description

technical field [0001] The invention belongs to the field of medical applications, in particular to the application of biguanide drugs in the preparation of drugs for preventing or reducing pulmonary fibrosis. Background technique [0002] Lung cancer is a malignant tumor with the highest morbidity and mortality worldwide. Non-small cell lung cancer (NSCLC) accounts for 80%-85% of all lung cancer cases; epidermal growth factor receptor (EGFR) and anaplastic lymphoma kinase (ALK) in It plays an important role in the occurrence and development of NSCLC. Targeted drugs represented by EGFR tyrosine kinase inhibitor (TKI) and ALK-TKI have achieved significant curative effect on specific NSCLC patients, but researchers have found that serious complications will occur during TKI treatment -- Interstitial pneumonia: At present, there is no effective clinical measure to prevent interstitial pneumonia caused by EGFR-TKI and ALK-TKI. Therefore, finding effective measures to prevent ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K31/155A61P11/00
Inventor 何勇李力
Owner THE THIRD AFFILIATED HOSPITAL OF THIRD MILITARY MEDICAL UNIV OF PLA
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com